Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Eli Lilly (LLY) and Beohringer Ingelheim's investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. It is the first biosimilar insulin recommended for E.U. approval. It has the same amino acid sequence as Sanofi's Lantus (insulin glargine).
The European Commission's final decision is expected in ~2 months.